Sjacobs, Thank you for referencing tonysd57's

Sjacobs,

Thank you for referencing tonysd57's post which brings important , fresh (last Friday) information from NP.

For completeness, I am copying below my comments to tonysd57 post:

Thanks for sharing the information. This are great news, however I think you don't understand the magnitude of the importance of the deal, less the meaning of a potential agreement.

The finalization of a commercialization agreement would mean that, once the BLA is submitted & approved and production is ramped up, CYDY will start receiving royalties.

CYDY needs some money to arrive to finance till BLA, a deal would mean this s taken care of.

In the mean time there are lots of "golden eggs" to be laid soon , to use your terminology:

- Safety data for 700 mg
- Monotheraphy
- mTNBC resuts with patient(s)
- NASH animal results and possible partnership with BP
- PrEP (Thailand, US Army)

I don't know about you but, I have seen and own many OTC and otherwise companies trading at several multiples current valuation only in hope of one product making it to market (with only one product in the pipeline as well).

Maybe you where expecting a quick several Billion BO and take your money to the bank, however the more indications Leronlimab probes to be therapeutically beneficial the higher the price tag will be when BP comes begging to CYDY's door.

If they don't come … well, the SP then will give you a wide smile. Or so I hope.

The important takeaways from his post (and Nader's comments) IMHO are:

1) Deal is still ingoing and the non-binding term sheet has been extended two weeks.
2) It is a very long term deal: 12 years !!!
3) It is for BOTH mono and combo (we were wondering about that) for whole of USA. An therefore it must be a very complex deal as mono will be a different ball-game.